Entera Bio (ENTX) CFO Yaacov‑Garbeli Dana Receives Option Award

What Happened
Yaacov‑Garbeli Dana, Chief Financial Officer of Entera Bio Ltd. (ENTX), received a grant of options covering 140,000 ordinary shares (reported acquisition price $0.00) on 2026-08-07. The grant is reported as a derivative award (transaction code A) rather than an immediate purchase or sale.

Key Details

• Transaction date: 2026-08-07 (Form filed same day).
• Transaction type/code: Grant / Award (derivative) — coded "A".
• Options granted: 140,000 options (reported acquisition $0.00).
• Vesting: Grant approved by the Board on May 7, 2026; vesting began May 7, 2026 — one‑third vests on May 7, 2027, remaining two‑thirds vest ratably quarterly over the next two years. Full acceleration upon a Change in Control per the 2018 Equity Incentive Plan. (See footnote F1.)
• Shares/options owned after transaction: Not specified in this Form 4.
• Timeliness: Filing lists the same report and transaction date (2026-08-07), indicating a same‑day report.

Context
This filing documents an option grant (a compensation award), not an exercise or sale. The reported $0.00 acquisition reflects the award reporting on Form 4; it does not mean immediate free shares or that options were exercised — exercise price and any tax/vesting events are governed by the company's equity plan and the terms noted above.